Reported Earlier, Allarity Therapeutics Faces Nasdaq Delisting for Stock Price Below $1
Reported Earlier, Allarity Therapeutics Faces Nasdaq Delisting for Stock Price Below $1
On June 18, 2024, Allarity Therapeutics, Inc. (the "Company") received a letter from the Nasdaq Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has not complied with the Nasdaq Listing Rule 5550(a)(2) which is the requirement that for 30 consecutive business days the bid price for the Company's common stock close above the $1 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.
2024年6月18日，Allarity Therapeutics公司（以下称“公司”）收到了纳斯达克股票市场LLC（以下称“纳斯达克”）的纳斯达克上市资格工作人员（以下称“工作人员”）的一封信，指出公司未遵守纳斯达克上市规则5550(a)(2)的要求，要求公司的普通股连续30个工作日的买盘收盘价超过每股1美元的最低买盘要求，以继续纳斯达克资本市场的纳斯达克上市。
The Company intends to request a hearing before a Nasdaq Hearings Panel (the "Panel") at which it will request continued listing pending its return to compliance. The Company's hearing request will stay the suspension of trading and delisting of the Company's common stock pending the conclusion of the hearing process. Consequently, the Company expects its common stock to remain listed on the Nasdaq Capital Market at least until the Panel renders a decision following the hearing. There can be no assurance that the Panel will grant the Company's request for a suspension of delisting or continued listing on the Nasdaq Capital Market.
公司打算请求纳斯达克听证会（以下简称“听证会”），并要求在公司恢复合规性期间继续进行上市交易。公司的听证请求将保留公司的普通股停牌和终止上市的决定，直到听证过程结束。因此，公司预计其普通股至少会在听证会作出决定之前继续在纳斯达克资本市场上市。无法保证听证会将批准公司暂停终止上市或在纳斯达克资本市场上继续上市。